NCT06799078Active, not recruiting
Racial Disparities in Antidepressant Treatment After a Psychiatric Consultation
Racial Disparities in Antidepressant Initiation, Titration, and Adherence After Receiving a Psychiatric Consultation
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
Patients from black, indigenous, and people of color (BIPOC) communities are reported to have lower rates of antidepressant adherence and response. The investigators have a limited understanding of why this disparity exists. The majority of outpatient psychiatric consultations are one-time assessments that provide treatment recommendations to the primary care provider. It is important to identify whether there are racial differences in accessing and adhering to recommended treatment plans to provide more equitable care. To the investigators' knowledge, there are no studies that examined racial differences in access and barriers to receiving antidepressant treatment after a one-time psychiatric assessment. This study focuses on patients who were diagnosed with major depressive disorder during a psychiatric consultation 3 months prior. We are examining whether there are racial differences in being a) recommended an antidepressant, b) started/switched to a recommended antidepressant, c) treated at a therapeutic dosage, d) adherence to treatment, and e) whether sociodemographic factors, discrimination in medical settings, and patient perception of depression and antidepressant treatment moderate these differences. This study will inform the development of treatment strategies that minimize racial disparities in the treatment of depression.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 23 Jan 2025
- Start date
- 4 Mar 2024
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- Centre for Addiction and Mental Health
- Diseases
- Depression
- NCT number
- NCT06799078
What you commit to
- Study type: Observational
- Planned participants: 60
- From 4 Mar 2024 to the primary completion date, 31 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of a life-time diagnosis of bipolar disorder or schizophrenia
Other
- Potential participants with a suicidal plan or intent whose consulting psychiatrist determined are in need of immediate clinical attention (e.g., referral to CAMH ED, voluntary or involuntary hospitalization)
- Acute psychosis (e.g., MDD with psychotic features)
Who the study is looking for
- Able and willing to sign and date the informed consent form
- Stated willingness to comply with all study procedures
- Age 18 years and older
- Diagnosis of depression in a psychiatric consultation at CAMH in the last 3 months
- Not currently followed by a psychiatrist
- Able to complete the REDCap questionnaire in English using the internet
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Addiction and Mental Health Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.